Recently, we reported that extract of Dalbergia sissoo made from leaves and pods have antiresorptive and bone-forming effects. The positive skeletal effect attributed because of active molecules present in the extract of Dalbergia sissoo. Caviunin 7-O-[b-Dapiofuranosyl-(1-6)-b-D-glucopyranoside] (CAFG), a novel isoflavonoid show higher percentage present in the extract. Here, we show the osteogenic potential of CAFG as an alternative for anabolic therapy for the treatment of osteoporosis by stimulating bone morphogenetic protein 2 (BMP2) and Wnt/b-catenin mechanism. CAFG supplementation improved trabecular microarchitecture of the long bones, increased biomechanical strength parameters of the vertebra and femur and decreased bone turnover markers better than genistein. Oral administration of CAFG to osteopenic ovariectomized mice increased osteoprogenitor cells in the bone marrow and increased the expression of osteogenic genes in femur and show new bone formation without uterine hyperplasia. CAFG increased mRNA expression of osteoprotegerin in bone and inhibited osteoclast activation by inhibiting the expression of skeletal osteoclastogenic genes. CAFG is also an effective accelerant for chondrogenesis and has stimulatory effect on the repair of cortical bone after drill-hole injury at the tissue, cell and gene level in mouse femur. At cellular levels, CAFG stimulated osteoblast proliferation, survival and differentiation. Signal transduction inhibitors in osteoblast demonstrated involvement of p-38 mitogen-activated protein kinase pathway stimulated by BMP2 to initiate Wnt/b-catenin signaling to reduce phosphorylation of GSK3-b and subsequent nuclear accumulation of b-catenin. Osteogenic effects were abrogated by Dkk1, Wnt-receptor blocker and FH535, inhibitor of TCF-complex by reduction in b-catenin levels. CAFG modulated MSC responsiveness to BMP2, which promoted osteoblast differentiation via Wnt/b-catenin mechanism. CAFG at 1 mg/kg / day dose in ovariectomy mice (human dose B0.081 mg/kg) led to enhanced bone formation, reduced bone resorption and bone turnover better than well-known phytoestrogen genistein. Owing to CAFG's inherent properties for bone, it could be positioned as a potential drug, food supplement, for postmenopausal osteoporosis and fracture repair. Osteoporosis has been called as a silent epidemic, characterized by reduced bone mineral density (BMD) and deterioration of bone micro-architecture that leads to enhanced bone fragility and increased risk of fracture.
in the risk of non-vertebral fractures by about B50%. However, PTH has shown black box warning of osteosarcoma in small animals. 6 For anti-resorptive raloxifene, the only SERMs are currently approved for osteoporosis that reduces spine fractures. 7 It also reduces the risk of hormone-positive breast cancer, 8 but its effect on cardiovascular disease remains uncertain. 9 Alendronate (ALN) increased the formation of fibroblastic colonies in cultures of rat bone marrow. 10 Combination therapy of PTH with ALN have shown synergistic effect on BMD, which is not fully supported by some observational studies. 11, 12 With available literature, further investigation is needed on the long-term risks, benefits of these drugs and development of novel therapies.
The aim of this study was to investigate alternative anabolic drugs for the treatment of osteoporosis. We have identified a novel isoflavone glucoside, caviunin 7-O-[b-D-apiofuranosyl-(1-6)-b-D-glucopyranoside] that has been abbreviated as CAFG, which is extracted from leaves of Dalbergia sissoo Roxb. 13 It belongs to the legume family (Fabaceae). 14 Here we show that this potent flavonoid could act like a bioactive molecule and could counteract the deleterious effects of estrogen deficiency occurring during menopause in women. CAFG's potential to induce osteogenesis was measured biochemically by assessing the activity of alkaline phosphatase (ALP) and then mineralization. 13 Overall, data show that CAFG, a novel isoflavonoid, enhanced osteogenic activity more and at much lower doses as compared with its structural analog genistein. Interestingly, CAFG is not estrogenic, instead promoted osteoblastic differentiation by activating the bone morphogenetic protein 2 (BMP2)-Wnt/b-catenin signaling pathway. We also show that CAFG modulates the cortical bone repair process after drill-hole injury by enhancing the function and differentiation of osteoblast.
Results
Dose determination of CAFG. Figure 1a shows the structural differences between CAFG (MW ¼ 668), caviunin (MW ¼ 374.34) and genistein (MW ¼ 270.2). Basic skeleton of the molecules is the glycine isoflavone; however, CAFG additionally contains two sugar moieties attached to it. 13 Dose validation by subcutaneously injecting CAFG at doses of 0.5, 1.0, 5.0 and 10 mg/kg body weight for 3 consecutive days shows increased expression for osteogenic genes (ALP, Runt-related transcription factor 2 (Runx2) and collagen type 1 (COL1), Figure 1b ) at both 1.0 and 5.0 mg/kg dose with no stimulation at either low dose of 0.5 mg/kg or highest dose of 10 mg/kg. Therefore, further experiments were carried out at doses of 1 and 5 mg/kg of CAFG.
CAFG prevents bone loss in estrogen deficiency model and improves biomechanical strength. Oral administration of CAFG shows its appearance in blood after 3.0±0.5 h with a maximum concentration (Cmax) of 160.23 ng/ml. The drug showed AUC value of 1528.91 ± 107ngxh/ml showing rapid absorption (data not shown).
Data of isolated bones by three-dimensional (3D)-mCT show that 6 weeks of ovariectomy (OVx; estrogen withdrawal) induced deterioration of the trabecular micro-architecture owing to destruction of the trabecular bone in the tibia proximal region (Figure 1d ), femur epiphysis and Lumber-5 (L-5) vertebrae (Supplementary Data). Treatment with CAFG and GEN at 1 and 5 mg/kg dose exhibited well-developed trabeculae, comparable to the control Sham þ vehicle and standards PTH, ALN. Quantification of these data at the tibial proximal sites shows significantly increased bone volume/ tissue volume (BV/TV; Figure 1e ), trabecular thickness (Tb.Th; Figure 1f ), trabecular number (Tb.No; Figure 1g ) and decreased trabecular separation (Tb.Sp.; Figure 1h ) and structural model index (SMI; Figure 1i ), as compared with OVx þ vehicle group that had significantly reduced ( À 80%) BV/TV, Tb.No, Tb.Th and increased Tb.Sp. and SMI. Interdose comparisons show that 1 mg/kg dose was more effective in increasing BV/TV (Po0.05) as compared with the 5 mg/kg dose. Overall, data suggest that 1 mg/kg oral dose of CAFG and 5 mg/kg of GEN for 6 weeks treatment were effective enough for more robust changes as compared with other doses of CAFG or GEN. CAFG could not surpass the positive effects as achieved by either PTH or ALN on bone but it showed comparable response.
Biomechanical strength data showed that CAFG dose dependently, especially 1 mg/kg dose in femur mid-diaphysis region, that is, cortical region of bone, increased femur breaking strength and energy versus the OVx group (Po0.001, Po0.01) ( Table 1 ) and increased L-5 stiffness and energy when compared with all other groups that were comparable to PTH and ALN (Table 1) .
CAFG induced new bone formation in mice. Parameters of new bone formation, mineral apposition rate (MAR) 15 and bone formation rate (BFR) 15 over unit bone surface area (BFR/BS) were reduced to B65% in OVx mice compared with the Sham group (Po0.001) as in Table 1 . CAFG, GEN and PTH treatment for 6 weeks increased BFR/BS in OVx mice (Figure 1j ). Inter-dose comparisons within group shows that 1 mg dose of CAFG increased bone formation to B65% more versus the OVx group and B13% more than CAFG (5 mg dose). As compared with 1 mg/kg dose of GEN, double the amount of BFR/BS was achieved with CAFG at 1 mg/kg (Table 1 ). (Figure 1k) . 16 However, 6 weeks of CAFG treatment to OVx group significantly lowered back the levels of this marker to B30%, indicating attenuation of bone turnover and thus resorption. CAFG (1 mg/kg/day) was more effective in lowering down the serum OCN levels as compared with GEN (Po0.05; Figure 1k ).
CAFG elicits no uterine estrogenicity. OVx resulted in reduction in all uterine parameter (wet uterine weight, luminal area and epithelial cell height), which is shown in Figure 1l . 17, 18 These mice on treatment with either 1 or 5 mg/kg/day dose of CAFG, GEN, PTH and ALN for 6 weeks exhibited no change in uterine weight indicating no hyperplasic effect compared with OVx (Table 1) .
Bone marrow cells (BMCs) after treatment with CAFG induced cell proliferation, differentiation and mineralization. CAFG increased cell proliferation at 1.0 mg/kg/day (Po0.001) and GEN at 5.0 mg/kg/day (Po0.01) compared with OVx group (Figure 2c ) assessed by 5-Bromo-2 0 -deoxyuridine (BrdU) assay. The measurement of cell viability and proliferation of treated BMCs revealed that all treated compound has more cell proliferation compared with OVx group (Figure 2c) . For further experiments, 1 mg/kg/day dose for CAFG and 5 mg/kg/day dose of GEN were used. Figure 2a shows that BMCs from the OVx group resulting in B30% decreased differentiation of BMCs toward osteogenic line as seen by ALP assay. CAFG at 1 mg/kg/day (Po0.001) and 5 mg/kg/day(Po0.01) doses significantly promoted differentiation of BMCs toward osteoblast with maximum stimulation at 1 mg/kg/day dose (B60%) Comparison with GEN, PTH and ALN shows that CAFG stimulates differentiation of cells comparable to the sham (Figure 2a ). Data were corroborated by mineralization assay (Figure 2b upper panel).
CAFG increased expression of osteogenic genes with decreased expression of osteoclastogenic genes in long bones. CAFG significantly (Po0.01) increased the expression of osteogenic genes, osteoprotegerin (OPG, Figure 2d ) and OCN gene (Figure 2e ). Analysis of expression of resorption marker gene shows that OVx resulted in increased expression of RANKL (receptor activator of nuclear factor kappaB ligand), TRAP (tartrate-resistant acid phosphatase) and RANK (receptor activator of nuclear factor kappaB). Whereas the expression was reduced by CAFG at 1 mg/kg/ day, GEN at 5 mg/kg/day, PTH and ALN (Figures 2f and g ) up to Sham.
CAFG decreases enhanced resorption in ovariectomized mice. TRAP staining of decalcified tibia bone revealed a massive increase in osteoclast number (Oc/Bs) and osteoclast surface (Os/Bs) in OVx group, which significantly recovered after treatment with CAFG and GEN. CAFG at 1 mg/kg/day dose has decreased osteoclast number (Po0.01) and osteoclast surface area (Po0.01), which is comparable to positive control groups (Figures 2h-j) . Table 1 Effects of various treatment groups for 6 weeks on different bone parameters of osteopenic mice using MTT (3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) in articular chondrocytes from newborn mice pups (1-to 2-day old) 19 ( Figure 3a ). At 100 pM or 1.0 pM, increase in proliferation was plateau off. Overall, CAFG was not toxic to the chondrocytes. Estimation of the chondrogenic effect was done by micro-mass culture. Alcian blue staining specific for chondrocytes (Figure 3b) shows that with CAFG treatment at 1.0 mM and 10 nM there is a greater deposition of proteoglycans and increased chondrogenic activity by day 14, whereas by day 7, there are no changes in the cells (Figure 3b ). Quantitative real-time PCR (Q-PCR) assessment of cartilage-specific genes Sox9 (early chondrogenic marker), 20 aggrecan (cartilage-specific proteoglycan core protein) 21 and Runx2 (proliferates chondrocytes), 22 at days 7 and 14 post CAFG treatment shows that 10 nM concentration significantly increased the expression of all the three genes as compared with the 1.0 mM concentration (Figure 3c ). Data were further corroborated at the protein level for Sox9 and Runx2 ( Figure 3d ). Overall, in vitro data imply that CAFG is an effective accelerant for chondrogenesis, which was further tested in the in vivo system. CAFG accelerated repair of cortical bone after drill-hole injury in mouse. Our in vitro data in chondrocytes suggested that CAFG could have a potential in fracture healing. Therefore, doses of 1 and 5 mg/kg/day were tested in the drill hole as shown in Figure 4a . For confirmation of osteoporotic bone before generation of drill-hole defect, micro-computed tomography (m-CT) was performed 23 that shows that OVx mice have less trabecular bone, disorganized trabecular structure and thinning of cortical bones compared with Sham mice (data shown in Table 2 ). CAFG treatment at doses of 1 and 5 mg/kg/day increased mineral deposition (measured from the intensity of calcein labeling in the drill hole; Figures 4b and c) as early as 11th day post fracture as compared with controls (day 0; Figure 4c ). The OVx group with drill hole showed the same effect in response to CAFG treatment but bone formation was significantly less when compared with Sham group (Figure 4c ). Data were verified by m-CT of drill-hole area (Figure 4d ), which showed 2D and 3D images generated by m-CT with increased BV/TV and Tb.No and decreased Tb.Sp. and SMI evidenced by significantly more callus being formed in the drill hole after CAFG treatment as early as on day 11th (Figures 4e and f) . It led to predominantly occupied mineralized callus, and the defect region was partially bridged in the Sham groups. But as compared with the 5 mg/kg/ day, 1 mg/kg/day had significantly more effect. Rate of callus formation of Sham group versus the OVx group shows that OVx mice had lower mineral deposition (39.0% less) than the Sham group; however, within the OVx group, CAFG at both the doses of 1 and 5 mg/ kg/day increased mineral deposition. Results were consistent with Q-PCR data with increased expression of osteogenic genes Runx2, BMP2, BMP4, OCN and COL1 mRNA (Figure 4g ). Expression of genes peaked significantly with 1 mg/kg/day on day 11 as compared with the 5 mg/kg/day dose. Increased mRNA expression of OCN was complimented with the increased serum levels of OCN (Figure 4h ). Overall, CAFG significantly contributed to the healing process in bone as observed in both Sham and OVx group. Effects of CAFG on p38 mitogen-activated protein kinase (MAPK) activation and BMP2 secretion in osteoblasts. CAFG stimulated osteoblast differentiation by increasing ALP production (Figure 5c ). This ALP activity was completely inhibited by p-38 MAPK inhibitor SB203580. Consistent with the observation that SB203580 blocked CAFG-induced ALP activity in osteoblast. CAFG stimulated phosphorylation of p-38 MAPK as early as at 12 h and attaining peak phosphorylation at 24 h (Figure 5d ), these findings were corroborated by western blot analysis at the same time points (Figure 5e ). CAFG increased BMP2 expression, a potent stimulator of osteogenesis in timedependent manner with the maximum stimulation being at 24 h (Figure 5f ). CAFG-induced BMP2 expression was inhibited in the presence of noggin (an endogenous BMP2 antagonist) at mRNA, protein and secreted BMP2 levels in conditioned media (Figures 5g-i) . Assessment of BMP2-dependent genes in the presence of CAFG shows that Smad1 and ALP expression levels were abrogated by noggin in mice calvarial osteoblast cells (Figure 5j ), indicating that CAFG-induced Smad-1 phosphorylation (Figure 5l ) is BMP2 dependent. Further, since BMP function activates Smad-1 proteins to stimulate expression of target gene Runx2. We used mouse full-length dual luciferase reporter system to test the effects on osteogenic differentiation in response to CAFG (Figure 5k ). Our data show that CAFG induced the osteogenic activity as early as 6 h by activation of pRunx2-Luc promoter of osteoblast in time-dependent manner that was maintained upto 24 h as evident also at protein level (Figures 5k and l) . To prove that CAFG stimulation is dependent on MAPK activation, we checked BMP2 expression in the presence of SB203580 that significantly attenuated the CAFG-induced increase in BMP2 expression from osteoblast (Figure 5m ), suggesting that MAPK activation is a prior event than BMP2 expression. Together, data presented demonstrate that CAFG induces BMP2 secretion via the p-38 MAPK pathway in osteoblasts and the resultant increase in the secreted BMP2 in turn may lead to osteoblast differentiation in a para/autocrine manner.
CAFG induced osteoblastic protein via canocincal Wnt/b-catenin signaling. Evidences suggest that Wnt signaling pathway modulates differentiation, proliferation and mineralization in bone formation as a downstream of BMP. 24, 25 CAFG at 10 nM concentration significantly induced the expression of Wnt3a, Lrp5, GSK3b and b-catenin and significantly attenuated the expression of Dkk1, sclerostin and phosphorylated GSK3b levels in cultured osteoblast cells (Figure 6a) . The above results were corroborated by expression seen at the protein level and quantitation of the same by densitometric analysis (Figures 6b and c) .
Caviunin-based isoflavonoid prevents bone loss P Kushwaha et al Fluorescence labeling data show that CAFG-induced nuclear localization of b-catenin required for transcription of target genes. BMP inhibitor noggin alone or in the presence of CAFG (increased when compared with noggin alone) blocked CAFG-induced nuclear localization of b-catenin in osteoblast cells, implying that BMPs mediate the nuclear localization of b-catenin induced by CAFG (Figure 6d ). Nuclear localization of b-catenin was quantified by western blot analysis (Figure 6e) showing that nuclear/cytoplasmic ratio was significantly higher with CAFG treatment as compared with that of noggin alone or CAFG þ noggin treatment (Figure 6f ). Osteoblasogenesis by CAFG through activation of b-catenin/Wnt signaling was confirmed by blocking it by exogenous addition of recombinant Dkk1 (Figures 6g-i (Figure 7c ). Protein data corroborated the TRAP mRNA levels that were significantly downregulated as quantified by densitometry analysis (Figures 7d and e) . Altogether, data show that CAFG inhibited osteoclastogenesis of murine BMCs by inhibiting their differentiation and maturation. 26 
Discussion
Our previous study demonstrated that osteogenic effects imparted by the extract of Dalbergia sissoo in the estrogen withdrawal osteoporotic model were due to the presence of a novel analog CAFG present in maximum amount. We confirm that CAFG's ability to act as a dual acting compound stimulates osteoblast proliferation, survival and differentiation, simultaneously inhibits osteoclast formation and their differentiation in bone, suggesting positive skeletal effect.
In vivo CAFG has osteogenic effect in adult ovariectomized mice. Under the circumstance of estrogen-dependent skeletal growth, CAFG treatment resulted in dose-dependent increase in differentiation of osteoprogenitor cells and mineralization of BMCs, expected to favor bone formation. 27 As a result, we observed increased MAR and BFR (resulting from expansion of bone marrow osteoblast pool) by dynamic histomorphometry in diaphysis femur of CAFG-treated mice. In agreement with dynamic histomorphometry data, m-CT (static histomorphometry) demonstrated increased trabecular bone gain by CAFG during the course of skeletal growth in mice compared with controls. Further, increased femoral periosteal bone deposition by CAFG had functional consequence in increasing bone biomechanical strength as CAFG dose-dependently increased femoral and vertebral force and stiffness. To understand detailed regulation of bone resorption, we assessed osteoclastogenesis from BMCs and bone. OVx resulted in increased resorption as seen by increased osteoclast number and activity characterizes postmenopausal bone loss. CAFG reduces the differentiation of osteoclasts around the bone surface and in vitro from BMCs comparable Caviunin-based isoflavonoid prevents bone loss P Kushwaha et al to Sham. Together, our data so far suggest that CAFG that lack uterine estrogenic effect stimulates bone formation in vivo, thus facilitating skeletal growth and acts as a dual acting compound, as it stimulates bone formation as well as inhibits bone resorption as evident by high expression of OPG and low expression of RANKL in treated group's bone marrow osteoblast cells. CAFG has anabolic role in bone formation and primary osteoporosis in female mice. Fracture healing is a complex process and osteoporotic bone has been reported for recurrent fracture. Fracture repair includes chondrogenesis and intramembranous ossification.
28,29 Therefore, we studied the effect of CAFG on chondrocyte cells to see whether it also affected the bone-healing process. CAFG at 10 nM concentration was not toxic and increased the proliferation of chondrocyte cells by inducing expression of BMP2, SOX9 and aggrecan sequentially and then promote the synthesis of proteoglycan of chondrocyte and thus chondrogenesis.
30 À 32 CAFG enhanced biosynthetic activities and cartilage-specific gene expression, indicating that CAFG may be a potential promoting compound for cartilage-induced injury-like fracture or tissue engineering.
As drill-hole injury model of long bone seems suitable for analyzing the healing process quantitatively and investigating chondrocyte differentiation in vivo. 23, 33, 34 Our data, by fluorochrome labeling, show that bone regeneration in the drill hole was diminished in OVx mice, compared with Shamoperated group, which could be due to the reduced osteoblast function under estrogen deficiency. The same study showed that CAFG treatment of either Sham or OVx mice significantly augmented the process of filling up by newly generated bone in the drill hole. This finding was complemented by several m-CT parameters (BV/TV, Tb.Th, Tb.No., Tb.Sp. and SMI) that indicated a more compact assembly and preferred plate-like structure (low SMI) of the newly formed bone of CAFG-treated mice. Overall, these data indicate that CAFG accelerates the bone-healing process after injury of long bones.
To specifically know the molecular target of CAFG, we next characterized the cellular signaling events being activated by CAFG. CAFG triggers BMP2-canonicalWnt/b-catenin signaling in osteoblasts that resulted in the stimulation of osteoblast differentiation and mineralization. Although BMP2 signaling component is distinct from the known Wnt/b-catenin signal transduction pathway, they may stimulate processes that cooperate with activated b-catenin to promote osteoblast differentiation. 24, 35 The ultimate outcome of the Wnt activation after treatment with CAFG resulted in the following sequence of events: increase of b-catenin nuclear translocation, and as Wnt activation is highly dependent on essential osteogenic transcription factor Runx2, we found activation of Runx2 promoter. The effect of CAFG was blocked by Dkk1, a blocker of Wnt/b-catenin receptor and FH535 inhibitor of b-catenin-TCF /LEF complex. Inhibition of b-catenin-TCF/LEF complex almost inhibited CAFG-induced BMP2 expression suggesting interdependence of the two signaling pathways. The effect of CAFG on signaling, function and gene expression of osteoblasts leading to possible anabolic action and antiosteoclastogenic effect is shown in Figure 8 . The end result of this orchestrated activity improved BMD and biomechanical properties.
Impetus to this data, we can conclude that CAFG has ability to impart osteogenic effect at much lower dose through BMP2-canonical/Wnt/b-catenin signaling. The human equivalent dose of CAFG translates into B0.081 mg/kg/day body weight. Therefore, for a 60-kg person, the daily requirement for CAFG is calculated to be B4.8 mg, which is easily achievable. Moreover, CAFG devoid of uterine estrogenicity and has pronounced effect on fracture healing. Therefore, its positioning as fracture healing and anti-osteoporotic agent is alluring.
Materials and Methods
Reagents and chemicals. Cell culture media and supplements were purchased from Sigma-Aldrich (St. Louis, MO, USA). Human PTH (1-34) was purchased from Calbiochem (Pacific Center Ct, San Diego, CA, USA) and ALN was purchased from Sigma. All fine chemicals and inhibitors (SB203580, and Noggin) were purchased from Sigma-Aldrich. Dkk1 Recombinant exogenous protein was purchased from R&D systems (Minneapolis, MN, USA), FH535 (2,5-Dichloro-N-(2-methyl-4-nitrophenyl)benzenesulfonamide) was purchased from Tocris Bioscience (Moorend Farm Avenue, Bristol, UK) and p38 MAP Kinase ELISA kit was purchased from Cell Signaling Technologies (Danvers, MA, USA). BMP2 ELISA was purchased from R&D systems. ECL kit was purchased from GE Healthcare Bio-Sciences (Pittsburgh, PA, USA). Antibody was purchased from Abcam (Cambridge Science Park, Cambridge, UK). 36, 37 Mice calvarial cell culture. For each experiment, 1-to 2-day-old mice calvarial cells were used to harvest 10-20 calvarias at room temperature. Briefly, individual calvaria was surgically isolated from the skull, sutures were segregated (i) Secreted BMP2 levels were assessed in conditioned media after treatment with CAFG by ELISA. Data represent mean±S.E. from three independent experiments. *Po0.05, ***Po0.001 compared with control. (j) Relative mRNA expression of Smad1 and ALP after CAFG exogenous BMP2 (100ng/ml) and noggin (50 ng/ml) treatment at 24 h. (k) Activation effects of CAFG on BMP2 signaling pathway were tested using reporter construct P-Runx2-Luc. A full-length mouse Runx2 promoter construct was used to test this effect. Cells were transfected with construct for 24 h and treated with CAFG. Cell lysates were collected and luciferase activity was measured after 24 h. Normalized control Renilla was used and plotted as fold activity over untreated control. Data represent mean ± S.E. from three independent experiments; ***Po0.001 compared with control. (l) Western blot analysis of various osteogenic genes phospho-Smad1, Smad1, Smad4, Runx2 after 24 h treatment in mice calvarial osteoblast cells. Data normalized by internal control b-actin. (m) Relative mRNA expression of BMP2 after pretreatment with CAFG and SB inhibitor (10 mM). Data represent mean ± S.E. from three independent experiments. *Po0.05,**Po0.01 compared with control Caviunin-based isoflavonoid prevents bone loss P Kushwaha et al and adherent tissue material was cleaned by gentle scrapping. As described previously, 36 the pooled calvarias were kept for repeated digestion (15 min/ digestion) with 0.05% trypsin and 0.1% collagenase P to release cells. First digestion was discarded and cell was collected from next four digestions. Cells were cultured in a modified essential medium (a-MEM) containing 10% fetal calf serum (FCS) and 1% penicillin/streptomycin (complete growth medium). MCOs were allowed to reach 70-80% confluence for the experiments.
Animal. All animal care and experimental procedures were approved by the Institutional Animal Ethics Committee. Female balb/c mice (18±5 g) were obtained from the National Laboratory Animal Centre. Animals were kept in a 12-h light-dark cycle, with controlled temperature (22-24 1C) and humidity (50-60%) and free access to standard rodent food and water. 36 Cell proliferation assay. We assayed cell proliferation by using BrdU incorporation assay. BMCs of treated groups were seeded on 96 well plates to differentiate towards osteogenic lineage. After differentiation, cells were kept for 24 h to arrest growth with serum-free media. BrdU (10 ng/ml) was added to the media. Then the cells were incubated for 4 h. The cells were washed, fixated and then stained with the BrdU antibody by using a BrdU staining kit (Roche Applied Sciences, Branford, CT, USA) following the manufacturer's instruction. O.D. (Optical Density) has measured at 450 nM. 36 Alkaline phosphatase activity (ALP) and mineralization assay of BMCs. At the end of the different treatments, mice were killed and BMCs from the femora were flushed out in osteoblast differentiation medium containing 10 À 7 M dexamethasone (bone marrow differentiation medium). Cells were seeded (2 Â 10 6 cells Á per well) onto 12-well plates in bone marrow differentiation medium. BMCs were cultured for 21 days with a change of medium every 48 h. At the end of the experiment, ALP activity was measured at 405 nm and mineralized nodules were stained and quantified at 405 nm, as described for the mice calvarial osteoblast cells. 36 q-PCR. SYBR green chemistry was for quantitative determination of various genes following an optimized protocol described before. The design of sense and antisense oligonucleotide primers was based on published cDNA sequences using the Universal ProbeLibrary (Roche Applied Sciences). Primer sequences are listed in Table 1 . cDNA was synthesized with the RevertAid cDNA synthesis kit (Fermentas, Austin, TX, USA) using 2 mg total RNA in 20 ml reaction volume. For Q-PCR, the cDNA was amplified using Light Cycler 480 (Roche Molecular Biochemicals, Indianapolis, IA, USA). 36 Oral bioavailability studies in Balb/c mice. Adult female Balb/c mice were used for this study. The animals were given a 1 mg/kg bolus dose of CAFG by oral gavage and killed at 0, 15 min, 30 min,1 h, 2 h,3 h,4 h, 6 h, 8 h, 12 h and 24 h after treatment. Three animals were taken at each time point. Plasma was collected for the determination of CAFG levels. Data that represent the concentration-drug profile at 0 h time point were obtained from animals without any prior treatment. Sample processing was performed as described in previous study. 36 Studies on the in vivo expression of CAFG responsive genes. Ten 1-to 2-day-old mice were divided into three equal groups and given a subcutaneous injection of either CAFG (1 mg/kg/day and 5 mg/kg/day dose in 50 ml) or equal volume of vehicle (normal saline) for 3 consecutive days. At the end of the treatment, pups were euthanized, and individual calvaria were harvested and cleaned of adherent tissue materials by gentle scrapping. Total RNA was isolated, and Q-PCR for ALP, Runx2 and COL1 was performed as described earlier.
3D trabecular and cortical micro-architecture analysis by l-CT. Sky Scan 1076 microCT scanner (Sky Scan, Aartselaar, Belgium) was used to carry out m-CT scanning of excised bones as described before. The bone samples were scanned at a resolution of 9 mm and reconstruction was done using the Sky Scan Nrecon software. The X-ray source was set at 50 kV and 200 mA, with a pixel size of 9 mm. A hundred projections were acquired over an angle arrange of 180 1C. CTanalyser (CTAn, Skyscan) software was used to draw ellipsoid contours in selected trabecular bone. Mean intercept length method was used to calculate trabecular bone volume, Tb.N and Tb.Sp. of the distal femoral epiphysis (covering secondary spongiosa and the secondary ossification center), proximal tibial and lumber 5 vertebrae. Tb.Th and SMI were calculated according to the method of Hildebrand and Ruegsegger. 3D parameters were based on analysis of a Marching cubes-type model with a rendered surface. CTVol software was used to create 3D model of the bones. 36 Fluorochrome labeling and bone histomorphometry. Crosssections (50 mm thickness) of periosteal regions of undecalcified diaphysis tibial bone of each mouse were obtained using an Isomet-Slow Speed Bone Cutter (Buehler, Lake Bluff, IL, USA). Images were captured using Leica-Qwin software (Leica Microsystems Inc., Buffalo Grove, IL, USA) and bone forming rate/bone surface (BFR/BS) and MAR were calculated. Tetracycline was injected 30 (20 mg/kg) days before termination of treatment, whereas calcien (20 mg/kg) 24 h before termination of treatment. 36 For TRAP histochemistry, femur bones were fixed in 4% formaldehyde and decalcified using EDTA solution. The bones were dehydrated, sectioned in 5 mm thick size, deparaffined and TRAP staining was performed according to previously published protocol. Histological section of bone stained for TRAP activity was analyzed with bioquant software. Analysis of osteoclast number and osteoclast surface was performed according to standardized protocols of the American Society for Bone and Mineral. 38 Bone mechanical strength. Bone mechanical strength was examined by compression test of lumber 5 vertebrae (L5) and breaking strength of femur with bone strength tester model TK 252C (Muromachi Kikai Co. Ltd., Tokyo, Japan), according to our previously published protocols. Uterine histology and histomorphometry. The uterus of mice was weighed and fixed in 4% paraformaldehyde and dehydrated in ascending grades of isopropanol, cleared in xylene and embedded in paraffin wax using standard procedures. Transverse sections (5 mm) were stained with hematoxylin and eosin and representative images were captured. Total uterine area, luminal area and luminal epithelial height were measured using Leica Qwin-Semiautomatic Image Analysis software (Leica). 36 Bone biochemical marker analysis. Rat-MID OCN EIA (Immunodiagnostic Systems Limited, Boldon, UK) was performed using serum from treated and vehicle groups using manufacturer's protocol. 36 Osteoclast culture and TRAP Staining. In vitro osteoclastogenesis was carried out using a standard protocol. 18, 26, 38 Mouse BMCs were flushed from femur bone using a-minimum essential medium eagle (a-MEM). Cells were seeded in T 25 flask for overnight in osteoclast medium (a-MEM, 10% FCS, antibiotic, Earle's balanced salt solution, 10 ng/ml MCSF). After overnight incubation, non-adherent BMCs were seeded in 48-well plates at a density of 200 000 cells/well and cultured for 5-6 days in a-MEM containing 10% FCS, Earle's balanced salt solution, 50 ng/ml RANKL and 10 ng/ml MCSF and CAFG at 10nM concentrations. Medium was replaced after every 48 h, after 6 days of culture. Cells were washed with PBS and then fixed in 4% paraformaldehyde for staining and for RNA extraction using TRIZOL for analysis of TRAP and RANK mRNA levels by real-time PCR. Fixed cells were followed by TRAP staining using the standardized protocol. 38, 26 Cell viability assay of CAFG. The cytotoxicity of CAFG on bone marrow osteoblast and chondrocytes was examined by MTT assay. Treated groups were differentiated into osteoblast cells and assess the cell proliferation and viability. Articular chondrocytes of newborn mice pups (1-to 2-day old) were treated with different concentrations of CAFG for 2 and 4 days. The cell viability/cytotoxicity was determined by using MTT assay (OD at 570 nm).
Alcian blue staining. Mice articular chondrocyte cells are in pre-chondrocyte cells proliferative stage. At day 7 (columnar chondrocyte cells-highly proliferative stage) and day 14 (hypertrophic chondrocyte stage), chondrocytes culture cells were fixed with 4% paraformaldehyde for 15 min at room temperature and then incubated overnight with 0.1% alcian blue (pH 1-2). Excess stain was washed off with 3% glacial acetic acid with and pictures were taken. For quantitative analysis, bound alcian blue dye was extracted with 200 ml of 6 M guanidine HCl overnight at room temperature. The optical density of the extracted dye was measured at a wavelength of 630 nm. 39 Apoptosis assay. Mice calvarial osteoblast cells were cultured in 50-60% confluence by serum withdrawal for 3 h and treated with CAFG (10 nM) or without treatment for 24 h in a-MEM containing 0.5% FBS Annexin-V/PI staining for FACS analysis was carried out using Calbiochem Annexin-V-FITC Apoptosis Detection Kit (Calbiochem) according to the manufacturer's instructions. 36 Western blot analysis. Mice calvarial osteoblast cells were grown to 80% confluency followed by exposure to compounds (CAFG) for different time periods. Cells were washed with cold phosphate-buffered saline (vehicle), and whole-cell lysates were prepared by the addition of lysis buffer Sigma-Aldrich containing a protease inhibitor mixture Sigma-Aldrich. 30-50 mg of protein was loaded per lane and separated on a 10% polyacrylamide gel, followed by transfer to a PVDF membrane (Millipore, Billerica, MA, USA) by electroblotting. Membrane was blocked for nonspecific binding in 5% nonfat dry milk and followed by incubation with an primary antibody (Abcam) at 4 1C overnight. Membranes were washed and probed with a horseradish peroxidase-conjugated secondary antibody (Abcam) and visualized by an enhanced chemi-luminescence system (GE Healthcare Life Sciences, Lucknow, India) according to the manufacturer's instructions. Nuclear and cytosolic protein extraction experiment. Mice primary osteoblast cells were incubated in medium with CAFG, Noggin and CAFG þ Noggin for 24 h. Nuclear and cytosolic protein were extracted by different lysis buffer using the manufacturer's protocol (CelLytic NuCLEAR Extraction Kit, SigmaAldrich). These extracted proteins were immunoblotted with b-catenin (Abcam) for nuclear translocation. 36 Immunocytochemistry. Mice primary osteoblast cells were incubated in medium with CAFG, Noggin and CAFG þ Noggin and were grown on Lab-Tek Chamber Slides (Nunc, Penfield, NY, USA) for 24 h. For immunocytochemistry, cells were fixed with 4% formaldehyde followed by permeabilization with 0.1% Triton X-100 and incubation in primary antibody (b-catenin) for overnight. Alexa Flour-488 (Invitrogen, Carlsbad, CA, USA) used as secondary antibody. Fluorescence was captured ( Â 40) using fluorescent microscope (Eclipse 80i, Nikon, Tokyo, Japan), with the aid of appropriate filter (Excitation 495 nm and Emission 519 nm). 36 Luciferase reporter analysis. Runx2 luciferase vector and renilla were purchase from GeneCopoeia (Rockville, MD, USA). Primary mice calvarial osteoblast cells were plated onto 24-well plates. At 60-70% confluency, cells were transfected with Runx2 luciferase and renilla vector with 700 ng. After 24 h of post-transfection, cells were treated with or without CAFG in differentiating media. Lysates were then collected and luciferase intensity was determined using Dual assay luciferase kit (Promega Corporation, Madison, WI, USA). 
